THE PSYCHEDELICS NEWSLETTER
Our weekly newsletter provides unparalleled data, insights and intelligence on the global psychedelics industry, straight to your inbox. Find the latest commercial deals, understand the latest regulatory changes and discover the most impactful scientific discoveries. Subscribe for free now.
ISSUES
Issue 23
Exploring the potential to create ethical psychedelics companies, a DNA test to inform psychedelic therapies, and preparing for the PSYCH Investor Summit: Europe and Asia. Read more in Issue 23 of The Psychedelics Newsletter.
Issue 22
Four companies added to the world’s largest psychedelics exchange and adding Field Trip Health to the PSYCH Investor Summit: Europe and Asia. Learn more in Issue 22 of The Psychedelics Newsletter.
Issue 21
The Australian government has announced $15m of funding for psychedelic medicines in a boost to the domestic and international market. Learn more in Issue 21 of The Psychedelics Newsletter.
Issue 20
The first-ever ketamine-assisted psychotherapy clinic has opened in the UK while Field Trip Health has confirmed the closing of $95m of funding. All this and more in Issue 20 of The Psychedelics Newsletter.
Issue 19
Researchers have published the results of a global drug survey, revealing that the use of psychedelics to treat mental health conditions is increasing.
Issue 18
Researchers have published the results on the most comprehensive study on microdosing while European psychedelic companies have been given an edge in the international market.
Issue 17
The results of a study on the use of MDMA to treat alcohol addiction have been published this week, whilst reforms on the use of psychedelics continue to take shape across the US.
Issue 16
The PSYCH Investor Summit is now open for registration and you can apply for tickets in this week’s issue of our newsletter, which also includes the most important stories from across the industry.
Issue 15
The Psychedelics industry has hit a major milestone as a number of industry-leading businesses have been listed on a dedicated exchange, allowing shares to be traded freely.
Issue 14
PSYCH hits 25,000 subscribers to become industry’s fastest-growing newsletter while a number of major announcements on the advancement of research into psychedelic medicines have been made.
Issue 13
Following a breakout year for the psychedelic sector, the pharmaceutical industry is set to take on a more prominent role in the market in 2021 and beyond. Learn more and catch up with the latest investment trends and scientific findings in Issue 13 of The Psychedelics Newsletter.
Issue 12
The psychedelic compound known as DMT will be used in a trial to treat depression for the first time in the United Kingdom while MDMA has been proven to help people suffering from alcohol addiction. All this and more in issue 12 of the PSYCH Newsletter.
Issue 11
Gain access to every panel discussion from The PSYCH Symposium before time runs out and catch up on the latest news from across the international psychedelics industry in Issue 11 of The Psychedelics Newsletter, here.
Issue 10
Issue 09
The PSYCH Symposium is set to bring together leaders from across the international psychedelics industry who are set to discuss and debate the most important issues facing the sector.
Issue 08
Issue 07
Taking place 17-20 as part of Prohibition Partners LIVE, The PSYCH Symposium will bring together distinguished industry thought leaders, rising entrepreneurs and experienced policymakers.
Issue 06
Issue 05
An Oregonian Congressman supports a measure for the legalisation of psilocybin therapy and psychedelic decriminalisation awaits a response from the Canadian government.
Issue 04
Issue 03
Canada approves end-of-life psilocybin treatment for palliative patients while UK scientists and experts propose easing restrictions for medical psychedelics and Californian activists propose easing restrictions for medical psychedelics.
Issue 02
An attempt to block the Washington D.C. psychedelic initiative fails, therapists request approval to test psychedelics in Canada and Oregon gets set to vote on psilocybin for therapeutic use in November 2020.
Issue 01
Oregon psilocybin decriminalisation campaign and DC activists say they will qualify for the November ballot while the New Medical Psychedelics Working Group to lobby for ease in UK research restrictions.
THE LATEST INSIGHTS, STRAIGHT TO YOUR INBOX
Join industry insiders and subscribe for exclusive news, data and insights from across the psychedelics industry.